Pioneering In Vivo CAR T Cell Therapies
We are committed to improving the treatment experience for patients through the development of better, faster, more accessible cancer treatments. At Umoja, our team is harnessing the power of our VivoVec platform to generate chimeric antigen receptor (CAR) T cell therapies in vivo.
Our Science
Our flagship VivoVec platform generates CAR T cells directly in a patient’s body. Our drug product will be available immediately to patients, removing the typical weeks-to-months-long process for today’s ex vivo CAR T cell therapies.
In-House Manufacturing
We are the only in vivo CAR T cell therapy company that has invested in our own manufacturing capacity for our VivoVec in vivo CAR T cell therapeutics.
In-house manufacturing allows us to reliably and flexibly meet our supply needs, control our manufacturing costs and quality, rapidly translate our science into drug supply, and significantly de-risk our future commercial launch execution.
Our Pipeline
Our pipeline is focused on the treatment of cancers using our in vivo platform, with potential applications in other conditions.
News + Resources
We work at the leading edge of in vivo T cell engineering. Visit our news and resources page to learn more about our scientific journey and the evolution of our company.
Careers
We are focused on advancing the future of CAR T cell therapies. Learn more about our team of experts.